Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
Finerenone, sotagliflozin exert heart failure benefits despite renal dysfunction
Secondary trial analyses in patients with type 2 diabetes showed both finerenone and sotagliflozin had heart failure benefits across the spectrum...
News
SURPASS-4: ‘Twincretin’ tirzepatide surpasses insulin glargine in pivotal trial
Tirzepatide, a single-molecule, dual receptor agonist, maintained its pivotal-trial win streak in its fifth and final randomized test before...
News
To tackle obesity, up fitness and activity or lose weight?
Researchers promote a ‘weight-neutral approach to treating obesity-related health conditions.’
News
Dropping weight beneficial but some effects of obesity persist
People with healthy BMIs who report former obesity have a lingering, elevated prevalence of type 2 diabetes, according to data from a series of...
News
Men die more often than women after bariatric surgery
Men undergoing bariatric surgery tend to be older than women and have more comorbidities and perioperative mortality.
News
Primary goal in T2D should be weight loss, diabetologists say
Four diabetes and obesity experts make the case for targeting weight loss of at least 15% as a frontline treatment goal for many patients with...
News
Women with type 2 diabetes get fewer cardioprotective drugs than do men
“This is confirmation that women are less well managed than men when it comes to cardiovascular risk, especially if they have [type 2] diabetes...
News
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say...
News
STOP-DAPT 2 ACS: 1 month of DAPT proves inadequate for patients with recent ACS
Findings from a Japanese trial show 1 month of dual antiplatelet therapy and 11 months of clopidogrel monotherapy is inferior to 12 months of DAPT...
News
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its...
News
FIDELITY: Finerenone benefits patients with T2D across CKD spectrum
FIDELITY, a prespecified analysis of FIDELIO-DKD and FIGARO-DKD, showed finerenone cuts event rates in patients with normal eGFR and albuminuria...